In a NAFLD model, it is observed that there is a very slight amount of PPARα present that is confirmed by measuring mRNA and protein level of PPARα and is confirmed by comparing with the control group. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.